Vedolizumab as Induction and Maintenance Therapy for Ulcerative ColitisBrian G. Feagan, Asit Parikh, William J. Sandborn et al.|New England Journal of Medicine|2013Cited by 2.9k
Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging StudyAsit Parikh, Brian G. Feagan, Timothy Leach et al.|Inflammatory Bowel Diseases|2011Cited by 211
A Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of VedolizumabMaria Rosario, Irving H. Fox, Nathanael L. Dirks et al.|Clinical Pharmacokinetics|2017Cited by 158
Vedolizumab, a monoclonal antibody to the gut homing α4β7 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotypeCatherine Milch, Joseph R. Berger, Tim Wyant et al.|Journal of Neuroimmunology|2013Cited by 77
Fecal Calprotectin Responses Following Induction Therapy With Vedolizumab in Moderate to Severe Ulcerative Colitis: A Post Hoc Analysis of GEMINI 1Walter Reinisch, Tim Wyant, Brian Bressler et al.|Inflammatory Bowel Diseases|2018Cited by 40